RxDoctor Payments Data

Matthew Ramsey, MD

Ophthalmology · Maple Grove, MNNPI 1598092165

Payments from drug & device makers

$951in general payments, 2019–2025

Across 14 payments — averaging $67.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$310
  • Alcon$272
  • AbbVie$215
  • Rxsight Inc$66
  • Biotissue Holdings Inc.$28
  • Rayner Intraocular Lenses Limited$18
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$951100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$951 in reported general payments places this provider in the 65th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$188,242
Medicare patients
650
Services billed
1,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost75$38,270
RestasisCyclosporine15$18,740
Latanoprost916$14,528
Travoprost72$13,422
VyzultaLatanoprostene Bunod24$9,581
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$7,924
Brimonidine Tartrate200$5,690
Prednisolone Acetate102$4,156
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat212$4,062
Timolol Maleate262$3,891
Ketorolac Tromethamine89$1,359
Tobramycin-DexamethasoneTobramycin/Dexamethasone27$1,305
Ofloxacin63$869
Dorzolamide Hcl50$844
ErythromycinErythromycin Base64$782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$215$57,01090 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Maple Grove

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →